Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: SCHEDULE 14C
    To elect six directors to the Company’s Board to serve until the Company’s 2021 annual meeting of stockholders or until their successors are elected and qualified (“Election of Directors”);
    To change the name of the Company to “Mosaic ImmunoEngineering Inc.” (the “Name Change”);
    To effect a reverse stock split of all of the Company’s outstanding shares of Common Stock by a ratio of 1-for-500 (the “Reverse Stock Split”);
    To reduce the number of shares of Common Stock that the Company is authorized to issue from 600,000,000 shares to 100,000,000 shares (the “Authorized Share Reduction”);
    To file an Amended and Restated Articles of Incorporation of the Company (the “Amended and Restated Certificate”) to give effect to the Name Change, Reverse Stock Split, and Authorized Share Reduction (A copy of the form of the Amended and Restated Certificate is attached as Appendix A to this Information Statement);
    To adopt the Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”) (A copy of the form of the Amended and Restated Bylaws is attached as Appendix B to this Information Statement);
    To ratify the appointment of KMJ Corbin & Company LLP. as the independent registered public accounting firm of the Company for the fiscal year ending May 31, 2021;
    To adopt the 2020 Omnibus Incentive Plan (“2020 Plan”) (A copy of the form of the 2020 Plan is attached as Appendix C to this Information Statement);
    To hold a non-binding advisory vote on executive compensation; and
    To hold a non-binding advisory vote on the frequency of executive compensation advisory votes (collectively with the matters identified in Items 1 through 10 above, the “Corporate Actions”).

 

Share
New Message
Please login to post a reply